Johnson & Johnson Innovation - JJDC, Inc. and Johnson & Johnson filed Amendment No. 1 to Schedule 13G with the SEC on November 6, 2026, disclosing their beneficial ownership of common stock in Contineum Therapeutics, Inc. as of November 3, 2026.

Key Highlights

  • Aggregate beneficial ownership: The reporting persons jointly disclose 1,979,173 shares of Contineum Therapeutics common stock, $0.001 par value.
  • Percent of class: The 1,979,173 shares represent 5.6% of the class, based on 35,353,313 shares of Class A Common Stock outstanding as of October 30, 2026.
  • Shared power only: Both reporting persons report 0 shares with sole voting or sole dispositive power; all 1,979,173 shares carry shared voting power and shared dispositive power.
  • Direct and indirect ownership: According to the filing, the securities are directly beneficially owned by JJDC, and Johnson & Johnson may be deemed to indirectly beneficially own such securities as JJDC's parent.
  • JJDC is a wholly-owned subsidiary: The filing states that JJDC is a wholly-owned subsidiary of Johnson & Johnson, a New Jersey corporation.
  • Triggering event date: The date of the event requiring this filing is listed as November 3, 2026.

Johnson & Johnson and JJDC Disclose Ownership Position in Contineum Therapeutics

The filing is Amendment No. 1 to a Schedule 13G originally filed by the reporting persons on April 10, 2024. According to the document, Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"), a Delaware corporation, and Johnson & Johnson ("J&J"), a New Jersey corporation, are filing jointly under a Joint Filing Agreement that was included as Exhibit A to the original Schedule 13G.

The filing discloses that both reporting persons report beneficial ownership of 1,979,173 shares of Contineum Therapeutics common stock. The percentage calculation is based on 35,353,313 shares of Class A Common Stock outstanding as of October 30, 2026, as reported in Contineum Therapeutics' Form 10-Q for the period ended September 30, 2026, filed with the SEC on November 3, 2026. JJDC's principal office is listed at 410 George Street, New Brunswick, NJ 08901, and J&J's address is One Johnson & Johnson Plaza, New Brunswick, NJ 08933. Contineum Therapeutics is headquartered at 3565 General Atomics Court, Suite 200, San Diego, CA 92121.

The certifications included in the filing state that, to the best of the signatories' knowledge and belief, "the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities." The filing was signed by Jill McManus, Assistant Treasurer of JJDC, and Marc Larkins, Secretary of Johnson & Johnson, both on November 6, 2026.

What Was Disclosed

Johnson & Johnson Innovation - JJDC, Inc. and Johnson & Johnson filed an amended Schedule 13G on November 6, 2026, reporting shared beneficial ownership of 1,979,173 shares, or 5.6%, of Contineum Therapeutics common stock, with no sole voting or dispositive power claimed by either party.